What We Do

Develop new treatments for chronic diseases, in particular, cancer.

We currently have an exclusive license with the University of Bath (UK).

Together we co-own the intellectual property relating to our proteolytic proenzyme formulations.

Together with our scientific and oncology consultants, we have developed a rational, composite formulation... More

Propanc’s leading products, PRP and PRP-DCM, are novel, patented suppository formulations based on proteolytic proenzyme... More

Current drugs in the market offer, at most, a few months of extra life or tumor stabilization... More

Metastasis refers to the ability of cancer cells to penetrate into lymphatic and blood vessels... More

The chances of developing cancer increase as a person gets older because more time has been available... More

The management of cancer differs widely, with a multitude of factors impacting on the choice of treatment strategy... More

The strategy for the development of our technology is to undertake early stage non-clinical & clinical... More

Propanc has identified an enhanced version of PRP, designated PRP -DCM, which potentially offers improved... More

Our research project POP1, involves optimising additional formulations that have a similar mechanism... More

Our intention is to supply this treatment to markets worldwide & improve quality of life